John C. Jacobs - 23 Jan 2024 Form 4 Insider Report for NOVAVAX INC (NVAX)

Role
President and CEO, Director
Signature
/s/ Mark J. Casey, Attorney-in-Fact
Issuer symbol
NVAX
Transactions as of
23 Jan 2024
Net transactions value
-$170,796
Form type
4
Filing time
25 Jan 2024, 17:00:09 UTC
Previous filing
25 Jan 2023
Next filing
26 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVAX Common Stock Options Exercise +83,197 83,197 23 Jan 2024 Direct F1
transaction NVAX Common Stock Tax liability $170,796 -40,093 -48% $4.26 43,104 23 Jan 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVAX Restricted Stock Units Options Exercise $0 -83,197 -33% $0.000000 166,393 23 Jan 2024 Common Stock 83,197 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F2 The RSUs subject to this grant under the Plan will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the January 23, 2023 grant date, in each case subject to continued employment through such vesting date.